Showing results 1 to 3 of 3
Title | Author(s) | Issue Date | |
---|---|---|---|
380MO A phase II trial of atezolizumab, bevacizumab, pemetrexed and carboplatin combination for metastatic EGFR-mutated NSCLC after TKI failure Proceeding/Conference:Annals of Oncology | 2020 | ||
2021 | |||
2021 |